Tirzepatide Dosage Guide

Tirzepatide is the first dual GIP/GLP-1 receptor agonist — activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors in a single molecule. Developed by Eli Lilly, it is marketed as Mounjaro (for type 2 diabetes) and Zepbound (for weight management). Tirzepatide has demonstrated weight loss results that exceeded Semaglutide in head-to-head clinical trials.

Tirzepatide is a synthetic peptide based on the native GIP sequence but engineered to also activate GLP-1 receptors. A C20 fatty acid moiety enables albumin binding, extending its half-life to approximately 5 days and enabling once-weekly dosing. This guide covers titration schedules, reconstitution for compounded formulations, injection technique, side effect management, stacking considerations, and safety.

Use our Peptide Dosage to assist with reconstitution and dose calculations for compounded tirzepatide.

How the Dual Mechanism Works

For a complete overview of its mechanism and research, see our full Tirzepatide profile. New to peptides? Start with the Beginner's Guide to Peptides.

Titration is not optional — it is a core part of the tirzepatide protocol. Both Mounjaro and Zepbound use the same dose escalation schedule: 2.5mg increments every 4 weeks. Never skip dose escalation steps.

Mounjaro / Zepbound Titration Schedule

Compounded Tirzepatide Titration (Typical Protocol)

Brand-name Mounjaro and Zepbound come in pre-filled pens — no calculation needed. Compounded tirzepatide is supplied as a lyophilized powder that must be reconstituted with bacteriostatic water. The concentration depends on how much water you add to the vial.

Quick Reference — 10 mg Vial

Quick Reference — 30 mg Vial

Quick Reference — 60 mg Vial

Tirzepatide's dosing varies depending on the primary treatment goal. All protocols begin with the same 2.5mg starting dose and follow the titration schedule. The target maintenance dose differs by indication.

Weight Loss

The FDA-approved protocol for chronic weight management (Zepbound) targets a maintenance dose of 10–15mg/week. In the SURMOUNT-1 trial, participants on 15mg/week lost an average of 22.5% of body weight at 72 weeks. Weight loss is dose-dependent — higher maintenance doses produce greater results but also more GI side effects during titration.

• Target dose: 10–15mg/week
• Titration: 16–20 weeks (2.5mg increments every 4 weeks)
• Route: SubQ injection, once weekly
• Duration: Ongoing (weight regain is common after discontinuation)
• Key requirement: Adequate protein intake (1.2–1.6g/kg/day) and resistance training to preserve lean mass

Type 2 Diabetes (Glycemic Control)

For type 2 diabetes, the Mounjaro prescribing information recommends titrating from 2.5mg to a target dose of 5–15mg/week based on glycemic response. Many patients achieve adequate HbA1c control at 5–10mg and do not need to escalate further.

• Target dose: 5–15mg/week (based on glycemic response)
• Titration: Follow Mounjaro schedule; assess HbA1c at each dose level
• Route: SubQ injection, once weekly
• Duration: Long-term (chronic disease management)
• Monitoring: HbA1c and fasting glucose every 3 months during titration

Weight Maintenance (Post-Goal)

After reaching goal weight, some providers cautiously reduce the dose to find the lowest effective maintenance dose. This approach aims to balance weight maintenance with minimizing side effects and cost. Evidence on dose reduction for maintenance is limited.

• Target dose: 5–10mg/week (may be lower than active weight-loss dose)
• Approach: Gradual dose reduction with monitoring; increase dose if weight regain occurs
• Key requirement: Established diet and exercise habits before attempting dose reduction
• Caution: SURMOUNT-4 showed significant weight regain after discontinuation; complete cessation is not recommended without a transition plan

Tirzepatide is designed for long-term use. Unlike peptides that are cycled (on/off), tirzepatide for both diabetes and weight management is intended as ongoing therapy. The SURMOUNT-4 trial demonstrated that discontinuation leads to significant weight regain — approximately 14% over 52 weeks.

Treatment Phases

What Happens After Discontinuation

• Appetite returns — GIP/GLP-1 receptor stimulation ceases within 1–2 weeks of the last dose (half-life ~5 days)
• Weight regain — the SURMOUNT-4 data showed approximately 14% weight regain over 52 weeks after stopping tirzepatide
• Blood sugar rises — for type 2 diabetes patients, glycemic control will deteriorate without alternative management
• Gradual taper is preferred — stepping down through titration doses in reverse (15 → 12.5 → 10 → 7.5 → 5 → 2.5 → stop) over 8–12 weeks reduces the shock of abrupt appetite return

Common Side Effects (from SURMOUNT-1)

Titration Tips for GI Tolerance

• Eat smaller, more frequent meals — 4–5 small meals per day instead of 2–3 large ones
• Reduce fatty and fried foods — fat slows digestion further on top of tirzepatide's gastric-slowing effect
• Stop eating when satisfied, not full — the delayed gastric emptying means “full” hits later; overeating causes significant discomfort
• Stay hydrated — aim for 64oz+ (2L+) of water daily; dehydration worsens constipation and nausea
• Extend the titration — if side effects are limiting at any dose, stay at that dose for an extra 2–4 weeks before increasing
• Avoid lying down immediately after eating — upright posture reduces GERD and nausea
• Evening injection — injecting before bed may reduce the perception of nausea during peak drug levels

Serious Risks

• Pancreatitis — acute pancreatitis has been reported. Discontinue promptly if pancreatitis is suspected (persistent severe abdominal pain, with or without vomiting). Do not restart if pancreatitis is confirmed.
• Gallbladder disease — cholelithiasis (gallstones) and cholecystitis have been reported, likely related to rapid weight loss.
• Hypoglycemia — when used with insulin or sulfonylureas, risk of low blood sugar increases. Dose adjustments of concurrent medications may be required.
• Acute kidney injury — reported in patients with dehydration from GI side effects. Maintain adequate hydration.
• Diabetic retinopathy complications — rapid improvement in glycemic control can temporarily worsen diabetic retinopathy. Monitor eye health.
• Hypersensitivity reactions — serious hypersensitivity reactions including anaphylaxis and angioedema have been reported.

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis — use with extreme caution or avoid
• Pregnancy — discontinue at least 2 months before a planned pregnancy due to the long half-life
• Breastfeeding — not recommended during nursing
• Severe gastrointestinal disease — gastroparesis or severe GI motility disorders
• Type 1 diabetes — tirzepatide is not approved for and should not be used in type 1 diabetes

Drug Interactions

• Insulin and sulfonylureas — increased risk of hypoglycemia; dose reduction of insulin/sulfonylurea may be required
• Oral medications — tirzepatide delays gastric emptying, which may affect the absorption rate of co-administered oral medications (particularly those with narrow therapeutic windows like warfarin or levothyroxine)
• Other GLP-1 agonists — do NOT combine with any other GLP-1 or dual agonist (Semaglutide, Liraglutide, dulaglutide, etc.)
• Warfarin — delayed gastric emptying may affect warfarin absorption; monitor INR closely during initiation and dose changes